InventisBio Co., Limited (SHA:688382)

China flag China · Delayed Price · Currency is CNY
21.39
+1.42 (7.11%)
Mar 6, 2026, 4:00 PM EST
23.00%
Market Cap 12.47B
Revenue (ttm) 37.33M
Net Income (ttm) -316.84M
Shares Out 578.35M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 20,361,470
Average Volume 13,360,648
Open 19.99
Previous Close 19.97
Day's Range 19.90 - 21.86
52-Week Range 14.60 - 49.68
Beta 0.09
RSI 38.98
Earnings Date Mar 28, 2026

About InventisBio

InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China. The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Taragarestrant, which is in Phase III clinical trial for the treatment of estrogen receptor positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer; and Gesorexel, which in Phase II cli... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 168
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688382
Full Company Profile

Financial Performance

In 2025, InventisBio's revenue was 37.33 million, a decrease of -77.89% compared to the previous year's 168.79 million. Losses were -316.84 million, 31.9% more than in 2024.

Financial Statements

News

There is no news available yet.